WO1999011791A3 - Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents - Google Patents

Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents Download PDF

Info

Publication number
WO1999011791A3
WO1999011791A3 PCT/US1998/018393 US9818393W WO9911791A3 WO 1999011791 A3 WO1999011791 A3 WO 1999011791A3 US 9818393 W US9818393 W US 9818393W WO 9911791 A3 WO9911791 A3 WO 9911791A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
necrosis factor
tumor necrosis
nucleic acids
binding agents
Prior art date
Application number
PCT/US1998/018393
Other languages
French (fr)
Other versions
WO1999011791A2 (en
Inventor
Preet M Chaudhary
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority to AU93764/98A priority Critical patent/AU9376498A/en
Publication of WO1999011791A2 publication Critical patent/WO1999011791A2/en
Publication of WO1999011791A3 publication Critical patent/WO1999011791A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective binding agents.
PCT/US1998/018393 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents WO1999011791A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU93764/98A AU9376498A (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92463497A 1997-09-05 1997-09-05
US08/924,634 1997-09-05

Publications (2)

Publication Number Publication Date
WO1999011791A2 WO1999011791A2 (en) 1999-03-11
WO1999011791A3 true WO1999011791A3 (en) 1999-09-30

Family

ID=25450466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018393 WO1999011791A2 (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Country Status (2)

Country Link
AU (1) AU9376498A (en)
WO (1) WO1999011791A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP1007659B1 (en) 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
EP0857782A3 (en) * 1997-01-27 1999-12-22 Smithkline Beecham Corporation Novel mammalian DD-1 gene
ATE362982T1 (en) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-CONTAINING RECEPTOR 4 (DR4), A MEMBER OF THE TNF RECEPTOR SUPERFAMILY WHICH BINDS TO TRAIL (APO-2L).
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DE69837606T2 (en) 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge CYSTEIN RICH RECEPTORS TRAIN
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
JP2002503444A (en) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー Ligand family genes
EP1044267A2 (en) * 1997-12-29 2000-10-18 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
DE19809978A1 (en) * 1998-03-09 1999-09-16 Basf Ag New soluble member of tumor necrosis factor receptor family, useful for identification specific modulators and for treating disease e.g. tumors
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
JP5550799B2 (en) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド TWEAK antagonists and TWEAK receptor antagonists and their use to treat immunological disorders
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CN100340292C (en) 1999-01-25 2007-10-03 比奥根艾迪克Ma公司 BAFF, inhibitors thereof and their use in modulation of B-cell response
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2001004139A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
MXPA02001264A (en) 1999-08-04 2002-07-22 Amgen Inc Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY.
EP2314694A3 (en) 1999-08-17 2013-12-11 Biogen Idec MA Inc. BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
WO2001030850A1 (en) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Umlr polypeptides
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
US20020068696A1 (en) * 2000-02-11 2002-06-06 Clive Wood Trade molecules and uses related thereto
WO2001058953A2 (en) * 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
DE60028830T2 (en) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
CA2408228A1 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001279055A1 (en) 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
RS51708B (en) 2001-05-11 2011-10-31 Amgen Inc. Peptides and related molecules that bind to tall-1
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences Antibodies against tumor necrosis factor delta (april)
DK2116259T3 (en) 2001-05-24 2012-05-21 Zymogenetics Inc TACI-immunoglobulin fusion proteins
JP4309758B2 (en) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Antibodies that immunospecifically bind to TRAIL receptors
AU2002366430B2 (en) 2001-07-03 2008-09-18 Genentech, Inc. Human DR4 antibodies and uses thereof
WO2003013578A1 (en) * 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003029420A2 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CN102793921A (en) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 Methods for treating tweak-related conditions
JP4574350B2 (en) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド APO-2 ligand / TRAIL variant and methods of use thereof
CN101899106A (en) * 2002-10-29 2010-12-01 阿纳福公司 The binding proteins for trimeric of trimerization cytokine
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN101014245A (en) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 Taj in neuronal function
WO2006017859A2 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
ATE508205T1 (en) 2004-08-06 2011-05-15 Genentech Inc TESTS AND PROCEDURES USING BIOMARKERS
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
JP2008525002A (en) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム BCMA polypeptides and uses thereof
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5562521B2 (en) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション Agents and methods relating to reducing resistance to apoptosis-inducing death receptor agonists
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
ES2432564T3 (en) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
AR059945A1 (en) 2005-08-09 2008-05-14 Zymogenetics Inc METHODS TO TREAT MALIGNAL AFFECTIONS OF B-CELLS USING A TACI-IG FUSION MOLECULA
JP5118037B2 (en) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Methods for the treatment and prevention of abnormal cell proliferation using TACI fusion molecules
ATE540318T1 (en) 2005-08-16 2012-01-15 Genentech Inc APOPTOSIS SENSITIVITY TO APO2L/TRAIL BY TESTING FOR GALNAC-T14 EXPRESSION IN CELLS/TISSUES
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
UA98462C2 (en) 2006-05-15 2012-05-25 Арес Трейдинг С.А. Methods for treating autoimmune diseases using a taci-ig fusion molecule
EP2379585A2 (en) 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
KR20120101050A (en) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 Treating basal-like genotype cancers
BR112012013330A2 (en) 2009-12-02 2017-03-28 Acceleron Pharma Inc compositions and methods for increasing fc fusion protein serum half life
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
KR101814852B1 (en) 2010-10-29 2018-01-04 다이이찌 산쿄 가부시키가이샤 Novel anti-dr5 antibody
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3305812B1 (en) 2013-03-14 2020-06-17 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHICHEPORTICHE Y. ET AL.: "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis", J. BIOL. CHEM., vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32401 - 32410, XP002108889 *
CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95", SCIENCE, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990 - 992, XP000676685 *
DATABASE GENBANK 19 July 1996 (1996-07-19), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:427152", XP002093795 *
DATABASE GENBANK 26 August 1996 (1996-08-26), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:472300", XP002093796 *
MACFARLANE M ET AL: "IDENTIFICATION AND MOLECULAR CLONING OF TWO NOVEL RECEPTORS FOR THE CYTOTOXIC LIGAND TRAIL", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 41, 10 October 1997 (1997-10-10), pages 25417 - 25420, XP002065148 *
PAN G ET AL: "AN ANTAGONIST DECOY RECEPTOR AND A DEATH DOMAIN-CONTAINING RECEPTOR FOR TRAIL", SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 815 - 818, XP002065147 *
ROKHLIN O.W. ET AL.: "Fas-mediated apoptosis in human prostatic carcinoma cell lines", CANCER RESEARCH, vol. 57, no. 9, 1 May 1997 (1997-05-01), pages 1758 - 1768, XP002093791 *
SHERIDAN J P ET AL: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors", SCIENCE, no. 277, 8 August 1997 (1997-08-08), pages 818 818, XP002075799 *
USLU R. ET AL.: "Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis", CLIN. CANCER RESEARCH, vol. 3, no. 6, June 1997 (1997-06-01), pages 963 - 972, XP002093792 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

Also Published As

Publication number Publication date
AU9376498A (en) 1999-03-22
WO1999011791A2 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2000001815A3 (en) Neurotrophic factors
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
HK1086598A1 (en) Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
CA2200423A1 (en) Novel estrogen receptor
HK1028773A1 (en) Interleukin-18 binding proteins, their preparationand use
AU9013998A (en) Tumor necrosis factor receptor ztnfr-5
DE69805237D1 (en) Tumor necrosis associated receptor, TR4
NL1010890C2 (en) Stabilizer mixture.
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
WO2001096565A3 (en) Binding agents: chimeric ligand/receptor proteins
WO2002072826A3 (en) Neurotrophic factors
GB9807256D0 (en) Functional protein compositions,emulsions based thereon and processes for their preparation
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
DE69841176D1 (en) Rtd receptor
WO1997011968A3 (en) A gene associated with liver neoplastic disease
WO2001012664A3 (en) Notch receptor ligands and uses thereof
AU9130598A (en) Tumor necrosis factor receptor ztnfr-6
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52
WO1998024896A3 (en) Muteins of obese protein
AU7753700A (en) Dna encoding prost 07 polypeptide
EP0588036A3 (en) Composition for isolating apamin receptors, apamin binding protein and uses thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA